Anixa Biosciences, Inc.
Company Snapshot: Anixa Biosciences, Inc.
Anixa, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Anixa is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. It is developing the Cchek™ platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. Anixa also continually examines emerging technologies in complementary or related fields for further development and commercialization. Additional information is available at www.anixa.com.
- Sep 8 2020 Anixa Biosciences to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference
- Aug 13 2020 Anixa and OntoChem Announce Identification of Additional Covid-19 Compounds
- Jul 28 2020 Anixa Biosciences Breast Cancer Vaccine Technology Nearing FDA Submission
- Jul 20 2020 Anixa Biosciences Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders